Table 1.
Descriptive Characteristics of Case Subjects and Control Subjects Included in Stage 1 (UK Biobank Primary and Signal Prioritization Analyses)
| Characteristic | ACO Case Subjects (n = 8,068) | Healthy Control Subjects (n = 40,360) | Control Subjects With COPD But No Asthma (n = 16,762) | Control Subjects With Asthma But No COPD (n = 26,815) |
|---|---|---|---|---|
| Age at recruitment, median (IQR), y | 60 (53-65) | 57 (49-63) | 62 (56-65) | 55 (48-61) |
| Sex, No. (%) | ||||
| Male | 4,179 (51.8%) | 17,598 (43.6%) | 9,147 (54.6%) | 9,703 (36.2%) |
| Female | 3,889 (48.2%) | 22,762 (56.4%) | 7,615 (45.4%) | 17,112 (63.8%) |
| Smoking status, No. (%) | ||||
| Ever smoked | 4,367 (54.1%) | 17,316 (42.9%) | 11,752 (70.1%) | 11,231 (41.9%) |
| Never smoked | 3,701 (45.9%) | 23,044 (57.1%) | 5,010 (29.9%) | 15,584 (58.1%) |
| Pack-years of smoking, median (IQR)a | 25.5 (13.5-39.5) | 15.8 (8.3-26.4) | 32.0 (19.0-45.5) | 16.5 (8.5-28.1) |
| Allergic rhinitis (including hay fever) or eczema, No. (%) | ||||
| Yes | 3,325 (41.2%) | 8,468 (21.0%) | 2,691 (16.1%) | 13,010 (48.5%) |
| No | 4,743 (58.8%) | 31,892 (79.0%) | 14,071 (83.9%) | 13,805 (51.5%) |
| Eosinophil count (median, IQR),b × 109 cells/L | 0.20 (0.13-0.32) | 0.13 (0.08-0.20) | 0.16 (0.10-0.24) | 0.21 (0.11-0.27) |
| Lung function, median (IQR) | ||||
| FEV1/FVC | 0.63 (0.58-0.67) | 0.78 (0.75-0.81) | 0.65 (0.61-0.68) | 0.77 (0.74-0.80) |
| % predicted FEV1 | 66.1% (56.5%-73.3%) | 97.3% (89.9%-105.6%) | 68.7% (60.0%-74.8%) | 90.8% (81.6%-100.0%) |
ACO = asthma-COPD overlap; IQR = interquartile range.
a
In ever smokers with nonmissing data, 3,270 of 4,367 case subjects, 11,196 of 17,316 main control subjects, 9,672 of 11,752 COPD-not asthma control subjects, 7,443 of 11,231 asthma-not COPD control subjects
b
In those with nonmissing data after cleaning as per Astle et al,32 n = 7,666 case subjects, n = 38,259 main control subjects, n = 15,845 COPD-not asthma control subjects, n = 25,292 asthma-not COPD control subjects.